A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

NCT05726864 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma
Colorectal Cancer
KRAS G12D
KRAS G12R
KRAS G12V
KRAS G12A
KRAS G12C
KRAS G12S
KRAS G13D
NRAS G12D
NRAS G12R
NRAS G12V
NRAS G12C
NRAS G12S

Interventions

DRUG: ELI-002 7P

Sponsor

Elicio Therapeutics